Literature DB >> 3156024

Ciprofloxacin distribution in prostatic tissue and fluid following oral administration.

J B Boerema, A Dalhoff, F M Debruyne.   

Abstract

The penetration of ciprofloxacin into prostatic tissue was studied following oral administration of 500 mg either once or repeatedly in 12-hourly intervals. Following single administration ciprofloxacin was rapidly absorbed from the gastrointestinal tract peaking 1-2 h after administration. Elimination from serum was slow, the half life being 4.3 h. No significant rise in serum concentrations was noticed following repeated administration. Ciprofloxacin was concentrated in the prostatic tissue, levels being on average twice as high as the corresponding serum concentrations. The ratios between prostate and serum levels following single and repeated administration were 227 and 214%, respectively. Intraindividual analysis of prostate concentrations in different areas of the prostatic gland revealed a homogeneous distribution within the prostate. Penetration of ciprofloxacin into prostatic fluid was studied in 11 patients 2-4.5 h after administration. At these points ratios between prostatic fluid and serum ranged between 1.5 and 450%.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156024     DOI: 10.1159/000238308

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  30 in total

Review 1.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  The role of quinolones in the treatment of chronic bacterial prostatitis.

Authors:  K G Naber
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection.

Authors:  M Grabe; A Forsgren; T Björk
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

Review 4.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

5.  Penetration of ciprofloxacin into female pelvic tissues.

Authors:  S Segev; E Rubinstein; J Shick; O Rabinovitch; M Dolitsky
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

6.  Single and multiple dose pharmacokinetics of ciprofloxacin.

Authors:  U Ullmann; W Giebel; A Dalhoff; P Koeppe
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

7.  Inappropriate breast secretions of possible bacterial etiology in the parous nonpuerperal female.

Authors:  J J Freeman; R H Altieri; A H Freeman; T Kuo; F Sardinha; C C Buckingham; J J Sklar; K Dyroff; A Floyd
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

8.  Ciprofloxacin concentrations in tonsils following single or multiple administrations.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

9.  Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues.

Authors:  G J Gerstner; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.